All News

back, LBP, spine, AS

Golimumab Effective in non-radiographic Axial Spondyloarthritis

d Jack Cush, MD

The GO-AHEAD study was designed to assess the long-term efficacy and safety of golimumab (GLM) in non-radiographic axial spondyloarthritis (nr-axSpA).  After the 16-week, placebo [PBO]-controlled double-blind phase, 189/198 (95.5%) entered the long-term extension (OLE) for 36 weeks wherein G

Read Article
malar lupus

Lupus Activity Affects Mortality

d MedPage Today

Each one-unit increase on a disease activity score during the first year after enrollment into a systemic lupus erythematosus (SLE) cohort was associated with a significant increased risk for death and organ damage during subsequent follow-up, researchers reported.

Read Article
RheumNow Podcast square

RheumNow Podcast – Coconspirators: RA and Lung Disease

d Jack Cush, MD

Dr. Jack Cush reviews and discusses more than a dozen news and journal articles from the past week on RheumNow.com.

Read Article
Rheums: Got a Rheumatology question or case for Jack Cush? Record it here and we'll feature it on an upcoming podcast. Tell us your name and where you practice rheumatology. https://t.co/wzNmOzH4VE https://t.co/UYWPeOvdd7

Links:

Dr. John Cush RheumNow ( View Tweet)
News Feature: Lupus Activity Affects Mortality https://t.co/lxWAHro0LK https://t.co/oIfLqCWSzI

Links:

Dr. John Cush RheumNow ( View Tweet)
Good Patient Focused overview of Raynauds phenomenon vs Raynauds disease. Not all blue fingers are Raynauds! "Diagnosing and treating Raynaud’s disease" https://t.co/4aKgu2Ika7

Links:

Dr. John Cush RheumNow ( View Tweet)

CARD8 SNP rs11672725 (OR 3) may be a Genetic Variant for AdultStill’s Disease. AOSD has unregulated NLR3 inflammasome activity. Study of 66 AOSD & 128 controls, showed AOSD to have low CARD8, higher caspase-1, IL-1β and IL-18; more systemic Sxs https://t.co/rpypR4cLfM

Links:

Dr. John Cush RheumNow ( View Tweet)

Hydroxychloroquine related hyperpigmentation appears as Blue or black discoloration of skin or mucosa, occurs in 7-30%; Recent report says ~5%; Risk factors include steroids, bruising, anti-coagulants and trauma - theyr slow to resolve if you D/C https://t.co/aTSBopIEQN

Links:

Dr. John Cush RheumNow ( View Tweet)

Dr. J Curtis discussing ACR’s COVID Vaccine guidance. Testing for antibodies may not be necessary at this time as common lab tests differ in what they target. #RNL2021 https://t.co/Xd0DYiwZEg
Robert B Chao, MD doctorRBC ( View Tweet)
Sign up for our Tuesday Night Rheumatology this week featuring lectures and talks presented at RheumNow Live 2021. #RNL2021 https://t.co/lpOUOqhnIE https://t.co/f1dSTWfOsX

Links:

Dr. John Cush RheumNow ( View Tweet)
Coconspirators: RA and Lung Disease Download this week's RheumNow podcast, where Dr. Cush reviews the news and journal articles for the last week. https://t.co/MJbfJANWwt https://t.co/PUqewOvBjZ

Links:

Dr. John Cush RheumNow ( View Tweet)
Clinical pearl: Bisphosphonates can cause posterior iritis (consider this in patients with negative labs and long term use of bisphosphonates.) Dr. Wang #RNL2021 @RheumNow

Dr. Rachel Tate uptoTate ( View Tweet)

Lilly has reported clinical success with Baricitinib (JAK inhibitor) in patients with alopecia. Two studies (BRAVE-AA1 and BRAVE-AA2) show statistically significant improvement in scalp hair regrowth with baricitinib compared to placebo. https://t.co/D0GE2cSzDZ

Links:

Dr. John Cush RheumNow ( View Tweet)

Register for Tuesday Night Rheumatology. This will feature excerpts from: Future Therapies in RA - Dr. Roy Fleischmann Difficult RA - Dr. Maya Buch RA Treatment Paradigms: EULAR 2019 and ACR 2020 Guidelines - Dr. Alan Matsumoto https://t.co/lpOUOqhnIE #RNL2021 #RheumNow https://t.co/9kdaJ3vfSd

Links:

Dr. John Cush RheumNow ( View Tweet)
"Lupus panniculitis appears like this and feels like wood! But... don’t forget about ddx of possible subcutaneous panniculitic T-cell lymphoma. #RNL2021" Thanks Dr. Robert Chao @doctorRBC for the great #RNL2021 coverage.

Dr. John Cush RheumNow ( View Tweet)

News Feature: BSRBR: Demyelinating Disease Following Anti-TNFα Therapy https://t.co/oHJXOa96Kn https://t.co/ucu9AsC8l3

Links:

Dr. John Cush RheumNow ( View Tweet)
#RNL2021 coverage from Dr. Rachel Tate @uptoTate Dr. Robert Wang: 91% of uveitis is non-infectious and located in the front of the eye - "anterior uveitis/iritis." 50% of anterior uveitis patients are +HLA B27! #RheumNow

Dr. John Cush RheumNow ( View Tweet)

BC, Canada study of Lupus mortality: 6,092 SLE pts followed for 17 yrs, there were 451 deaths. Compared to population, all cause mortality was nearly 2 fold higher (HR 1.85 (1.66-2.06); excess deaths from renal (HR 3.04), INFX (2.74) & CVD (2.05) https://t.co/I0kzXNeulH https://t.co/ZVNp4Ec2gC

Links:

Dr. John Cush RheumNow ( View Tweet)
Diary study of 79 FM, 86 RA, 33 w/ both FM/RA shows that compared to RA, pts with FM have worse daily well-being, negative affect, more isolation, inability to complete plan. FM had more perceived stigma and lower well-being. https://t.co/YZdhvYghuI

Links:

Dr. John Cush RheumNow ( View Tweet)

Sonelokimab is a novel trivalent nanobody aimed at IL-17A & IL-17F; tested at multiple doses vs Placebo or secukinumab in 383 plaque psoriasis pts: SON at doses 60-120 mg had efficacy similar to SEC; but SON had more Candida infx (17·4% vs 1.9% SEC) https://t.co/Nhh9UyX3i0

Links:

Dr. John Cush RheumNow ( View Tweet)

How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×